In this case resistance emerges via multiple, distinct genetic and transcriptomic mechanisms that bypass the tumour’s requirement for signalling via EGFR, suggesting tumour heterogeneity may play a role in mediating therapy resistance3. The gene discussed is EGFR; the disease is neoplasm.